L-Ornithine-L-aspartate (LOLA) is primarily used in the management of hepatic encephalopathy, a complication of advanced liver disease. Its mechanism centers on reducing elevated blood ammonia levels, which are a significant contributor to the neuropsychiatric manifestations of hepatic encephalopathy. LOLA enhances the urea cycle and glutamine synthesis in the liver and muscle, promoting ammonia detoxification. While jaundice itself is a clinical sign reflecting elevated bilirubin and impaired liver function, the underlying pathology often coincides with hepatic insufficiency and hyperammonemia, especially in cirrhosis or acute liver failure.

Clinical studies and guidelines recognize LOLA as a therapeutic agent for hepatic encephalopathy, but its use specifically for "jaundice" is less direct. The rationale for its use in jaundiced adults stems from the frequent overlap of hyperammonemia and hepatic dysfunction. Some clinical trials have shown that LOLA can improve liver function tests and reduce ammonia in patients with cirrhosis, which may indirectly benefit those with jaundice due to liver disease. However, LOLA does not directly lower bilirubin or treat the cause of jaundice itself. Systematic reviews (e.g., Cochrane) highlight its effectiveness in hepatic encephalopathy but do not support its use solely for jaundice.

In summary, the use of L-Ornithine-L-aspartate in jaundiced adults is supported by moderate scientific evidence when jaundice is associated with hepatic encephalopathy or significant liver dysfunction, but not for jaundice alone.